Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
6.60
+0.97 (17.23%)
May 15, 2025, 4:00 PM - Market closed
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Fulcrum Therapeutics stock ranges from a low of $2.00 to a high of $10. The average analyst price target of $4.50 forecasts a -31.82% decrease in the stock price over the next year.
Price Target: $4.50 (-31.82%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 6 | 6 | 5 | 5 | 5 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 10 | 9 | 9 | 9 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades $10 | Hold → Buy | Upgrades | $10 | +51.52% | May 15, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | -39.39% | Feb 26, 2025 |
RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -39.39% | Nov 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | -39.39% | Nov 14, 2024 |
RBC Capital | RBC Capital | Buy → Hold Downgrades $15 → $4 | Buy → Hold | Downgrades | $15 → $4 | -39.39% | Sep 13, 2024 |
Financial Forecast
Revenue This Year
n/a
from 80.00M
Revenue Next Year
27.13M
EPS This Year
-1.22
from -0.16
EPS Next Year
-1.30
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 83.8M | n/a | ||
Avg | n/a | 27.1M | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.09 | -1.17 | -1.20 | ||
Avg | -1.22 | -1.30 | -1.27 | ||
Low | -1.35 | -1.35 | -1.32 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.